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Introduction. RTOG 0330 was developed to address the toxicity of RTOG 9514 and to add thalidomide (THAL) to MAID
chemoradiation for intermediate/high grade soft tissue sarcomas (STSs) and to preoperative radiation (XRT) for low-grade STS.
Methods. Primary/locally recurrent extremity/trunk STS: ≥8cm, intermediate/high grade (cohort A): >5cm, low grade (cohort
B). Cohort A: 3 cycles of neoadjuvant MAID, 2 cycles of interdigitated THAL (200mg/day)/concurrent 22 Gy XRT, resection, 12
months of adjuvant THAL. Cohort B: neoadjuvant THAL/concurrent 50Gy XRT, resection, 6 months of adjuvant THAL. Planned
accrual 44 patients. Results. 22 primary STS patients (cohort A/B 15/7). Cohort A/B: median age of 49/47 years; median tumor size
12.8/10cm. 100% preoperative THAL/XRT and surgical resection. Three cycles of MAID were delivered in 93% cohort A. Positive
margins: 27% cohort A/29% cohort B. Adjuvant THAL: 60% cohort A/57% cohort B. Grade 3/4 venous thromboembolic (VTE)
events: 40% cohort A (1 catheter thrombus and 5 DVT or PE) versus 0% cohort B. RTOG 0330 closed early due to cohort A VTE
risk and cohort B poor accrual. Conclusion. Neoadjuvant MAID with THAL/XRT was associated with increased VTE events not
seen with THAL/XRT alone or in RTOG 9514 with neoadjuvant MAID/XRT.
1.Introduction
In1995,theRadiationTherapyOncologyGroup(RTOG)in-
itiated 9514, a phase II study of neoadjuvant MAID (Mesna,
Adriamycin, Ifosfamide, Dacarbazine) chemoradiation for
high-risk STS of the extremity and body wall. Patients
with large (≥8 c m ) ,h i g h - g r a d eS T Sw e r es c h e d u l e dt o
receive 3 cycles of neoadjuvant MAID chemotherapy with
interdigitated preoperative radiation therapy (44Gy given in
two 22Gy courses) followed by surgical resection and then
3 additional cycles of adjuvant MAID chemotherapy. The
results for 64 evaluable patients were published in 2006 [1].
With a median tumor size of 15cm, the overall limb salvage
rate was 91% and 23% had a complete pathologic response
followingsurgicalresection.Inaddition,theestimated5-year
overall survival was a promising 71.2%. However, this mul-
timodality regimen was not without signiﬁcant treatment-
related toxicity. Grade 4 toxicity occurred in 81% of patients,
13%experiencedsigniﬁcantwoundcomplications,andthere
were 3 treatment-related deaths.2 Sarcoma
Based upon the experience with 9514 and discussions
with Clinical Trials Evaluation Program (CTEP) at the NCI,
the Sarcoma Working Group within the RTOG developed
protocol 0330, which attempted to minimize the toxicity
seen with 9514, included low-grade tumors, incorporated
biologic endpoints, and added thalidomide to the systemic
chemotherapy regimen. As a “nontraditional” systemic ther-
apeutic agent, thalidomide was chosen for several reasons. It
hasbothantiangiogenicandimmunomodulatoryproperties.
Thalidomide is also a well-tolerated oral agent frequently
used in combination therapy for other cancers. Finally, there
appears to be a potential relationship between circulating
levels of antiangiogenic regulators (bFGF, VEGF,and endo-
statin) and STS with a potential correlation between high
VEGF levels and impaired survival [2, 3]. The purpose of
this paper is to report on the available results for 0330,
particularly the observed thromboembolic complications
from the use of thalidomide with multimodality therapy.
2.MaterialsandMethods
2.1. Patient Eligibility. Eligible patients were ≥16 years old
with a primary T2a or T2b STS (AJCC, 6th ed.) located
on the upper extremity (including the shoulder), the lower
extremity (including the hip), or the trunk. Patients with
locally recurrent STS were also eligible provided that there
was no evidence of metastatic disease and there had been
no prior primary tumor site radiation. Patients were divided
into cohort A and cohort B based upon the histologic grade
of the sarcoma. Cohort A consisted of patients with grade
3 or 4 (intermediate to high grade) STS ≥ 8cm in maximal
diameter. Cohort B included patients with grade 1 or 2 (low
grade) STS > 5cm in size. Given the planned adriamycin in
cohort A, patients also had to have acceptable heart function.
Due to the known thromboembolic risks and side eﬀects
associated with thalidomide, exclusion criteria for both
cohorts included a known history of deep vein thrombosis
or pulmonary embolus (except in patients where the cause
was directly related to foreign body implants, i.e, a central
venous catheter), a known hypercoagulable disorder, base-
line CTCAE v3.0 grade 2 or greater fatigue or other global
neurocognitive symptomatology, taking sedating drugs, not
agreeing to avoid sedating illegal “recreational” drugs or
alcohol greater than one drink per day, or known acquired
immune deﬁciency syndrome. Finally, given the teratogenic
eﬀects,pregnancywasanabsolutecontraindicationandboth
male and female patients agreed to follow all contraceptive
requirements.
2.2. Radiation Therapy. Preoperative radiation therapy for
cohort A (patients receiving MAID chemotherapy) consisted
of two courses of external beam radiation therapy (EBRT)
interdigitated between each course of MAID. Each course of
EBRT was to begin 3 days after completion of each cycle of
MAID and consisted of 22Gy in 11 fractions (once a day)
over 15 days. The total planned preoperative radiation dose
was44G yin22fractions.Thalidomidewast obegi v en7da ys
per week each evening before bedtime during the radiation
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Figure 1:TreatmentschemaforRTOG0330cohortA.Neoadjuvant
MAID(Mesna,Doxorubicin,Ifosfamide,DTIC) ×3cycles,concur-
rent thalidomide (THAL) and radiation therapy (XRT) × 2c y c l e s ,
followed by surgical resection, followed by adjuvant THAL for one
year (post-op boost XRT if a positive margin).
phase of the therapy but was not to be given concurrent
with the chemotherapy. Preoperative radiation therapy for
cohort B included 50Gy in 25 fractions, delivered at 2Gy
per fraction daily over 5 weeks. Thalidomide was to be given
7 days per week each evening before bedtime during the
radiation phase of therapy.
A postoperative EBRT boost was given for patients with
a positive margin. This consisted of 16Gy in 8 daily fractions
to the bed of the residual tumor (including a margin of
1cm).Aboostwasnotgivenforpatientswith100%necrosis.
Postoperative EBRT began approximately 2 weeks following
resection, assuming there was satisfactory healing of the
surgical wound.
Conventional radiotherapy simulated with a 2D simula-
torandconformalradiotherapyplannedwithaCTsimulator
were acceptable treatment techniques, but intensity modu-
lated radiation therapy (IMRT) and brachytherapy were not
permitted.
2.3. Chemotherapy and Thalidomide. Patients in Cohort
A were scheduled to receive a maximum of 3 cycles of
neoadjuvant MAID with concurrent thalidomide/radiation
therapy. This was followed by surgical resection and then
adjuvant thalidomide for one year. The treatment schema
is summarized in Figure 1. The study utilized the Common
Terminology Criteria for Adverse Events (CTCAE) version
3.0 for grading of all treatment related adverse events. The
3 cycles of MAID consisted of the following.
Mesna: 2500mg/m2/day as a continuous infusion for 4 days
starting on day 1 and repeated on day 22 and day 43 for 4
days.
Doxorubicin: 20mg/m2/day as a continuous infusion for 3
days starting on day 1 repeated on day 22 and day 43 for 3
days.
Ifosfamide: 2500mg/m2/day as a continuous infusion for 3
days starting on day 1 and repeated on day 22 and day 43 for
3d a y s .
DTIC: 225mg/m2/day as a continuous infusion for 3 days
starting on day 1 and repeated on day 22 and day 43 for 3
days.
G-CSF: 5mcg/kg/day subcutaneously starting on day 5 (24
hours after completion of chemotherapy) and continuing
daily until the WBC count recovered.Sarcoma 3
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Figure 2:TreatmentschemaforRTOG0330cohortB.Neoadjuvant
concurrentthalidomide(THAL)andradiationtherapy(XRT)(stop
THAL one week prior to surgery), followed by surgical resection,
followed by adjuvant THAL for 6 months (post-op boost XRT if a
positive margin).
At the beginning of the preoperative radiation phase,
thalidomide was started at 200mg/day. Thalidomide was
not administered during the MAID chemotherapy. Two
weeks after surgery or when the postoperative radiation
began (for the subset that needed a boost for positive
margins), thalidomide was restarted at 200mg/day (or at
the last well-tolerated dose). The postoperative thalidomide
was administered daily for one year (regardless of the boost
radiationschedule).Ifpatientsdidnotdevelopneuropathyat
the200mg/day dose, the treating physicianhad the option to
dose-escalate to 400mg/day during the postoperative phase.
Due to the thromboembolic risk associated with thalido-
mide, 81mg aspirin was taken each morning on the same
days as thalidomide if there were no contraindications. The
protocolalsocontaineddosemodiﬁcationrecommendations
for thalidomide toxicity. Patients with DVT were instructed
to hold the drug until resolution to less than or equal to
grade 1 toxicity, adequate therapeutic anticoagulation, and
were then supposed to be restarted at a 50% dose reduction
without further escalation.
Patients enrolled in cohort B were scheduled to receive
neoadjuvant concurrent thalidomide and radiation followed
by surgical resection and then adjuvant thalidomide for
6 months. Otherwise, thalidomide dosing, dose escalation,
toxicity adjustments, and concomitant low-dose aspirin
therapy were identical to cohort A. The treatment schema is
summarized in Figure 2.
2.4. Surgery. The goal of surgical therapy was an oncolog-
ically complete resection, ideally with limb and function
preservation, and negative margins, whenever achievable.
Surgical resection of the primary tumor was to be performed
42–56 days after the last radiation dose. If the ﬁnal pathology
revealed positive soft tissue margins (not bone, nerve, or
large blood vessels), surgical re-resection to obtain negative
margins was strongly encouraged if it was not felt to have
a major impact upon the patient’s functionality. As it was
felt that some extremity STS may require amputation simply
to obtain grossly negative margins, primary amputation was
not considered a local failure. However, amputation for a
local recurrence after previous attempted limb preservation
was scored as a local failure.
2.5. Statistical Analyses. The primary endpoint was treat-
ment compliance. In 9514, 89% of patients received the pro-
tocol dose of radiation and 79% received all 3 preoperative
cycles of MAID. For 0330, patients were considered compli-
ant if they received at least 95% of the preoperative protocol
Table 1: Patient and tumor characteristics for cohort A and B
patients in RTOG 0330.
Cohort A
(n = 15)
Cohort B
(n = 7)
Median age (years) 49 (range
20–75)
47 (range
39–81)
Gender
Male 8 (53.3%) 5 (71.4%)
Female 7 (46.7%) 2 (28.6%)
Median tumor size (cm) 12.8
(range 8.4–16.7)
10.0
(range 5.6–27.0)
Tumor site
Upper extremity 1 (6.7%) 0 (0.0%)
Lower extremity 11 (73.3%) 5 (71.4%)
Buttock/hip 2 (13.3%) 1 (14.3%)
Abdominal wall 0 (0.0%) 1 (14.3%)
Back 1 (6.7%) 0 (0.0%)
Histology
Liposarcoma 2 (13.3%) 3 (42.9%)
MFH 4 (26.7%) 0 (0.0%)
Synovial 2 (13.3%) 2 (28.6%)
MPNST 3 (20.0%) 0 (0.0%)
Other 4 (26.7%) 2 (28.6%)
MFH: malignant ﬁbrous histiocytoma; MPNST: malignant peripheral nerve
sheath tumor.
dose of radiation, all 3 cycles of MAID (if applicable), and
received thalidomide on 75% of the days during radiation
as prescribed per protocol. A compliance rate of least 75%
(for an individual cohort) was suﬃcient to consider a
regimen for further study. For planning purposes, a 10%
noncompliance rate was assumed with a noncompliance
rate of 25% considered the highest acceptable rate. With 22
evaluable patients in each cohort, the plan had a type I error
of 0.011 and type II error of 0.41.
In 9514, 78% of the 59 patients experienced a grade 4
hematologic toxicity and 3% had grade 5 toxicity (death).
Twenty percent experienced grade 4 nonhematologic toxic-
ities. In cohort A, no further increase in the rate of grade 4
hematologic toxicity was expected; an increase in the grade
4 nonhematologic toxicity rate to 35% would be considered
unacceptable. The RTOG had not previously conducted a
study in low-grade patients (cohort B). Therefore, the grade
4 nonhematologic toxicity rate was projected to be 10–15%
with 25% considered unacceptable.
3. Results
3.1. Patient Characteristics. From June 17, 2004 until closure
on March 21, 2007, 0330 accrued 23 primary STS patients
from 10 diﬀerent institutions. 16 patients were enrolled in
cohort A and 7 patients in cohort B. One patient in cohort
A was declared ineligible due to an unknown histologic
grade. Patient and tumor characteristics for both cohorts are
summarized in Table 1.4 Sarcoma
3.2. Neoadjuvant Chemoradiation and Surgical Resection. In
cohort A, 93.3% of patients (14/15) received the planned 3
cycles of neoadjuvant MAID chemotherapy. The remaining
patient was able to complete two cycles. All patients in
both cohorts received 100% of the prescribed preoperative
radiation dose (44Gy for cohort A and 50Gy for cohort
B). In addition, all 22 patients underwent surgical resection
of their primary STS. A pathologic complete response (no
viable tumor) was seen in 20.0% of cohort A (3/15) and
28.6% of cohort B (2/7, both were a synovial sarcoma).
On ﬁnal pathology, positive resection margins were noted
in 26.7% of cohort A (4/15) and 28.6% of cohort B
(2/7). No patients underwent re-resection for a positive
margin.
3.3. Neoadjuvant and Adjuvant Thalidomide. In cohort A,
the median number of days on neoadjuvant thalidomide
therapy was 30 (range 10–36), and the median cumulative
dose was 6,000mg (range 2,000–7,200). For cohort B,
the median number of days on preoperative thalidomide
therapy was 32 (range 3–36), and the median cumulative
dose was 11,600mg (range 600–19,400). Postoperatively,
60.0% of cohort A (9/15) received adjuvant thalidomide
with a median cumulative dose of 25,300mg (range 4200–
73,000). Similarly, 57.1% of cohort B (4/7) received post-
operative thalidomide with a median cumulative dose of
19,200mg (range 17,100–36,600). All patients in both
cohorts received 81mg aspirin daily during thalidomide
therapy.
3.4. Overall Treatment Compliance. In cohort A, 5/15
patients were considered non-compliant. In cohort B, 2/7
patients were considered noncompliant. Due to early study
closure, this endpoint could not be fully evaluated per the
protocol plan.
3.5. Treatment-Related Toxicity. Nonthromboembolic ad-
verse events for both cohorts are summarized in Table 2.
Excluding thromboembolic events, 27% of cohort A patients
experienced a grade 4 nonhematologic adverse event, similar
to the experience of RTOG 9514. Sixty-seven percent experi-
encedgrade3or4hematologictoxicity.Therewasnograde5
toxicity. The only hematologic toxicity in cohort B was grade
1 in 28.6% (2/7).
None of the patients in cohort B experienced a throm-
boembolic event. In contrast, 40% of patients in cohort
A (6/15) developed a thromboembolic complication. These
events are summarized in Table 3. All thromboembolic
events were in patients with a primary STS of the hip
(n = 1) or lower extremity (n = 5). Two thirds of all
events occurred in the preoperative setting: two bilateral
pulmonary emboli (PE), one catheter-associated upper
extremity deep venous thrombosis (DVT), and one inci-
dental ipsilateral lower extremity DVT noted on preoper-
ative restaging imaging. One of the patients who devel-
oped bilateral PE had not yet received any thalidomide
therapy. Postoperatively, two patients developed an ipsi-
lateral DVT within 30 days of surgery. There were no
deaths from any of the thromboembolic events. Five of
the patients were treated with anticoagulation and one of
the preoperative patients underwent placement of an IVC
ﬁlter.
Postoperative complications in cohort A included a
grade 3 non-infectious wound complication in one patient,
a grade 1 non-infectious wound complication in a second
patient, and a grade 3 joint infection and grade 2 soft
tissue necrosis of the lower extremity in a third patient.
In Cohort B, 1 patient developed a grade 3 noninfectious
wound complication and grade 3 blood infection, 1 patient
developed a grade 1 noninfectious wound complication and
grade 1 seroma, 1 patient developed a grade 2 non-infectious
wound complication, and 1 patient developed a grade
3s e r o m a .
4. Discussion
Local tumor control with limb preservation for patients with
high-risk STS has signiﬁcantly increased through a combi-
nation of improved imaging, the multimodality approach of
surgery and radiation therapy, and gradual improvements
in these techniques. In contrast to local control, overall
survival has not signiﬁcantly changed over time. The risk
for developing distant metastases with a high-grade STS is
directly proportional to tumor size (34% for 5.1–10cm, 43%
for 10.1–15cm, and 58% for 15.1–20cm) [4]. RTOG 9514
was initiated in 1995 to examine the eﬀects of intensive
neoadjuvant MAID chemotherapy interdigitated with split
courses of preoperative radiation followed by surgical resec-
tion and adjuvant systemic chemotherapy on local control
and overall survival for high-risk STS. In this study, limb
preservation was achieved in 92.2% of patients despite a
median tumor size of 15cm [1]. In addition, the pathologic
complete response rate was an impressive 27%. Although
there was no direct control group for comparison, the
71.2%estimated5-yearoverallsurvivalwasmuchbetterthan
historical outcomes for comparable patients. Unfortunately,
theseresultswerenotachievedwithoutsigniﬁcantmorbidity.
Grade 4 hematologic toxicity was seen in 78% of patients
and there were 3 treatment-related deaths. The signiﬁcant,
cumulative toxicity of this multimodality regimen was also
evident by the fact that only 59% of patients completed all 6
planned cycles of MAID chemotherapy (3 preoperative and
3 postoperative) and 25% did not receive any postoperative
chemotherapy.
In response to the results and limitations of 9514,
the RTOG developed 0330. Thalidomide was chosen as a
nontraditional therapeutic agent with antiangiogenic and
potentially immunomodulatory properties, oral adminis-
tration, and well-tolerated use in combination therapy for
other malignancies such as multiple myeloma. Similar to
9514, cohort A (large, high-grade tumors) was developed to
examine the eﬀect of concurrent thalidomide on preopera-
tive radiation therapy as well as whether or not long-term
adjuvant thalidomide would be better tolerated than several
cycles of postoperative MAID chemotherapy. RTOG 0330
also included large, low-grade tumors (cohort B) to evaluateSarcoma 5
Table 2: Nonthromboembolic adverse events for cohort A and B patients in RTOG 0330.
Cohort A (n = 15) Grade Cohort B (n = 7) Grade
A d v e r s e e v e n t 1234512345
Auditory/ear 0 100000000
B l o o d / b o n e m a r r o w 2155020000
C a r d i a c a r r h y t h m i a 1210001000
C a r d i a c g e n e r a l 1300010000
C o a g u l a t i o n 0000010000
C o n s t i t u t i o n a l s y m p t o m s3830013000
D e r m a t o l o g y / s k i n 2720013100
E n d o c r i n e 1000000000
G a s t r o i n t e s t i n a l 2830031000
Hemorrhage/bleeding 1 100011000
I n f e c t i o n 0220001200
L y m p h a t i c s 5100010000
M e t a b o l i c / l a b o r a t o r y 3520011000
M u s c u l o s k e l e t a l / s o f t t i s s u e 0400001200
N e u r o l o g y 2430004000
O c u l a r / v i s u a l 3000001000
P a i n 2800011000
Pending 1 011000000
P u l m o n a r y / u p p e r r e s p i r a t o r y 0200000000
S e x u a l / r e p r o d u c t i v e f u n c t i o n 0100000000
W o r s t n o n h e m a t o l o g i c 1571012400
(%) (6.7) (33.3) (46.7) (6.7) (0.0) (14.3) (28.6) (57.1) (0.0) (0.0)
W o r s t o v e r a l l 1266012400
(%) (6.7) (13.3) (40.0) (40.0) (0.0) (14.3) (28.6) (57.1) (0.0) (0.0)
Table 3: Thromboembolic adverse events in 6 patients in cohort A
of RTOG 0330.
Tumor
site
Adverse event
(AE)
AE
grade Timing Comment
LE
Catheter-
associated UE
DVT
3p r e o p prior to 3rd
cycle MAID
Hip Bilateral PE 4 preop 1st cycle MAID
(no THAL)
LE LE DVT 3 postop 4w e e k sp o s t o p
(ipsilateral)
LE LE DVT 3 preop presurgery MRI
(ipsilateral)
LE LE DVT 3 postop 1w e e kp o s t o p
(ipsilateral)
LE Bilateral PE 4 preop 2nd cycle MAID
LE: lower extremity; DVT: deep venous thrombosis; PE: pulmonary emboli;
preop: preoperative; postop: postoperative; MAID: Mesna/Adriamycin/
Ifosphamide/Dacarbazine; THAL: thalidomide; MRI: magnetic resonance
imaging; UE: upper extremity.
similar endpoints, albeit using thalidomide and radiation
without cytotoxic chemotherapy.
Prior to initiating 0330, there was concern regarding
the association of thalidomide with a high incidence of
venous thromboembolic events (VTE), such as deep venous
thrombosis (DVT), and pulmonary embolus (PE), when
used either alone or in combination therapy. A meta-analysis
of 3,322 multiple myeloma patients treated with thalido-
mide alone, dexamethasone alone, combination therapy,
or nonthalidomide/dexamethasone regimens showed that
thalidomide was associated with a 2.6-fold increased risk for
VTE while thalidomide with dexamethasone had an 8-fold
increased risk [5]. Even more pertinent to 0330 was data by
Zangari et al. showing that the incidence of DVT was 2.5%
in multiple myeloma patients treated with a dexametha-
sone/thalidomide combination chemotherapy regimen that
did not contain doxorubicin versus 16% percent in patients
treatedwiththesameregimenbutincludingdoxorubicin[6].
In the doxorubicin group, 35% of DVTs were associated with
central venous access. There was also one nonfatal PE.
Due to the high incidence of VTE with thalidomide
treatment for multiple myeloma, there has been interest in
whether or not anticoagulation or antiplatelet therapy can
reduce this risk. In a phase III study of newly diagnosed
multiple myeloma patients randomized to induction dox-
orubicin containing chemotherapy with or without thalido-
mide, several cohorts were created based upon whether6 Sarcoma
patients received anticoagulation prophylaxis with low-
dose coumadin (1mg per day) [7]. The rates of DVT
were 14% for chemotherapy alone/no thalidomide or anti-
coagulation, 34% for chemotherapy with thalidomide/no
anticoagulation, and 31% for chemotherapy with thalido-
mide/coumadin. The majority of DVTs occurred during the
ﬁrst cycle of treatment and coumadin did not reduce the risk
(P = 0.7). Following treatment with systemic anticoagula-
tion and resumption of chemotherapy, the DVT recurrence
rate in the chemotherapy alone arm was 5% versus 11%
in the thalidomide-containing group. A third cohort of
chemotherapy alone versus chemotherapy/thalidomide with
low-molecular-weight heparin (enoxaparin 40mg subcuta-
neous daily) had equal rates of DVT at 15% (P = 0.81).
The conclusion was that low-molecular-weight heparin,
but not low-dose coumadin, was eﬀective in reducing the
risk of thalidomide-associated DVT and that thalidomide-
containing therapy could be safely reinstituted following
DVT treated with anticoagulation. Data supporting an
antiplatelet approach includes a study from Baz et al. with
an initial VTE incidence of 28.6% in multiple myeloma
patients receiving pegylated doxorubicin, vincristine, dex-
amethasone, and thalidomide [8]. The protocol was then
amendedtoinclude81mgaspirindaily,producing3cohorts:
aspirin from the beginning of chemotherapy (group 1),
aspirin at some point after starting chemotherapy (group 2),
and no aspirin (group 3). The incidence of VTE was 19% in
group 1, 15% in group 2, and 58% in group 3. As groups
1 and 2 were not statistically diﬀerent, the hazard ratio for
VTE with any aspirin use as compared to no aspirin was
0.22 (P<0.001). There were also no bleeding complications
associated with aspirin use.
Given the complexities of administering daily outpatient
subcutaneous low-molecular-weight heparin over several
weeks, a decision was made to use low-dose aspirin (81mg)
to reduce the VTE risk in 0330. However, the greatest
challenge to deciding upon an appropriate VTE prophylaxis
regimen for 0330 was the paucity of available data regarding
expected baseline VTE rates during STS treatment. One
retrospective review of children undergoing sarcoma treat-
ment had a 11.5% VTE rate [9]. In a study of prophylactic
IVC ﬁlter placement prior to adult musculoskeletal tumor
surgery, the rates of DVT and PE were 11.8% and 0%,
respectively, in a subset of 17 STS patients [10]. A review
of VTE after orthopedic surgery in adult cancer patients
(including non-STS surgery) noted a DVT rate of 14.2% and
a PE rate of 0.6% that were comparable to these other studies
[11]. In the sarcoma subgroup (bone and soft tissue), 15.6%
ofpatientsdevelopedaDVT.Oneofthebetterassessmentsof
sarcomaVTEriskisaretrospectivestudyof252patientswith
a primary bone or STS (94 bone, 158 STS) [12]. The rate of
DVT was 3.9%, PE was 1.2%, and fatal PE was 0.4%. Similar
toourstudy, theirVTE patients hadaprimary tumorlocated
in the hip or lower extremity. Interestingly, 77% of the VTEs
occurred prior to the deﬁnitive surgical resection of the
sarcoma. In our study, 67% of cohort A VTEs also occurred
preoperatively, including one DVT prior to even starting
thalidomide therapy. As RTOG 0330 was based upon 9514, a
reasonable comparison group for cohort A would also be the
original 9514 patients. In 9514, there were only two grade 3
vascular adverse events (including one PE) for a VTE rate of
3.1% [1]. Although this would suggest that some of the VTE
risk in 0330 came from the addition of thalidomide to the
neoadjuvanttherapyregimen,inretrospect,itmayhavebeen
more prudent to administer daily low dose aspirin for VTE
prophylaxisduringallphasesoftheneoadjuvanttherapy,not
just the thalidomide.
5. Conclusion
So what was learned from 0330? Given the early closure of
the study and the limited accrual to both cohorts, it is not
possibletodrawanyconclusionsregardingtheeﬀectofeither
treatment regimen on survival. Cohort B closed due to poor
accrual, which was likely multifactorial, including the overall
low incidence of STS as well as limited interest in adjuvant
therapy trials for low-grade, lower-risk tumors. In cohort A,
40% of patients developed a VTE despite daily aspirin use
duringthalidomidetreatment.Evenexcludingoneeventthat
occurred prior to initiating thalidomide and one catheter-
related event, the rate of VTE was still 27%. As this rate is
comparable to the high rates of VTE seen with combination
chemotherapy/thalidomide for other cancers, daily low-dose
aspirin did not seem to eﬀectively reduce the VTE risk. VTE
also limited the ability to deliver the prescribed adjuvant
therapy (why 50% of cohort A patients did not receive
adjuvant thalidomide). Although almost all of the cohort
A patients were able to complete the planned treatment
course of neoadjuvant MAID/thalidomide/radiation and
there were no treatment related deaths, the pathologic com-
pleteresponseratewasonly20%.Consequently,thalidomide
did not appear to increase the biologic eﬀectiveness of
the preoperative chemoradiation to justify the potential
increased VTE risk. In contrast, none of the patients
in cohort B experienced a VTE with thalidomide alone.
Although patient numbers were very limited, the pathologic
complete response rate to neoadjuvant therapy in cohort B
was 29%, which is higher than one would expect for low-
grade STS undergoing preoperative radiation alone. This
raises a provocative question of whether thalidomide alone
could function as a radiosensitizer in the treatment of some
low-grade STSs.
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